May 2011

Hospitals have made astonishingly little progress, but CMS is forcing the issue
Picture a drug that has been compounded for decades and sold at a low price. The FDA approves a new formulation, and the price goes through the roof.
Many problems attributed to outcomes measurement result from poor planning before a program is initiated. A DM expert lays down some ‘must-do’ rules for success in this excerpt from Disease Management and Wellness in the Post-Reform Era, published by Atlantic Information Services Inc.
Health plans have many options to improve how they handle these costly therapies

Departments

LEGISLATION & REGULATION
Complex formula treats urban and rural areas differently
MEDICATION MANAGEMENT
Building provider incentives around drug performance is one way health insurance plans can ensure optimal use
TOMORROW’S MEDICINE
A definitive diagnosis requires a full brain biopsy, but imaging compounds may help identify the deposition of amyloid plaque, which is associated with the disease

Leave a Comment